- 64 次围观
产品图片
货号/SKU
NR-55307
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55307?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, P.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, P.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|DN SatherAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, P.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55307.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Brazil variant (P.1 lineage) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55307 lacks the signal sequence and contains 1196 residues (ectodomain) of the SARS-CoV-2 spike glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR?GSAS; residues 682 to 685) and KV?PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55307 is derived from the P.1 lineage of SARS-CoV-2, which includes L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and V1176F mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55307 has a theoretical molecular weight of 139,850 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2, Brazil variant (B.1.1.28, an ancestor of P.1) has been solved at 3.22 ? resolution (PDB: 7LWW).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence. In addition, the E484K mutation has been identified in escape mutants for convalescent antisera.
Each vial contains approximately 100 ?L of NR-55307 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Brazil variant (P.1 lineage) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55307 lacks the signal sequence and contains 1196 residues (ectodomain) of the SARS-CoV-2 spike glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR?GSAS; residues 682 to 685) and KV?PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55307 is derived from the P.1 lineage of SARS-CoV-2, which includes L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and V1176F mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55307 has a theoretical molecular weight of 139,850 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2, Brazil variant (B.1.1.28, an ancestor of P.1) has been solved at 3.22 ? resolution (PDB: 7LWW).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence. In addition, the E484K mutation has been identified in escape mutants for convalescent antisera.
Each vial contains approximately 100 ?L of NR-55307 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自严重急性呼吸综合征相关的穗状花序的重组形式的穗糖蛋白
冠状病毒2（SARS-COV-2），巴西变体（P.1谱系）在人胚胎肾HEK293细胞中产生，并通过固定化金属亲和层析纯化. NR-55307缺乏信号序列，含有1196个残基（Ectodomain）的SARS-COV-2穗糖蛋白;通过在Furin S1 / S2切割位点（RRARαGSAS;残基682至685）和KVαPP突变（残留物986和987;野生型编号），并包括T4 Folcon三聚化结构域，HRV3C，通过取代重组蛋白质蛋白酶切割位点和C末端Octa-组氨酸标签与Avitag?Bira Biotinylation受体序列融合. NR-55307衍生自SARS-COV-2的P.1谱系，其包括L18F，T20N，P26S，D118Y，R190S，K417T，E484K，N501Y，D614G，H655Y，T1027I和S糖蛋白中的V1176F突变相比到SARS-COV-2参考序列（Genpept：
qhd43416 ）. NR-55307有一个
理论分子量为139,850道尔顿. SARS-COV-2中三聚糖蛋白的晶体结构已在3.22埃分辨率（PDB： 7lww ）.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜.结构建模和小鼠研究表明N501Y增加了糖蛋白与ACE2的结合，导致SARS-COV-2毒力增加.此外，已在恢复突变体中鉴定E484K突变，用于康复抗血清.
每个小瓶在10mM Hepes，pH 7,150mM NaCl和2mM乙二胺 - 四乙酸（EDTA）中含有约100μl的NR-55307.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01